Novel avenues of drug discovery and biomarkers for diabetes mellitus

Journal of Clinical Pharmacology

Volumn 51, Issue 2, 2011, Pages 128-152

  Maiese, Kenneth ^a   Chong, Zhao Zhong ^a   Shang, Yan Chen ^a   Hou, Jinling ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; diabetes; oxidative stress

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; ERYTHROPOIETIN; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; TRANSCRIPTION FACTOR FKHR; WNT PROTEIN;

ALZHEIMER DISEASE; CELL SURVIVAL; DIABETES MELLITUS; DRUG DEVELOPMENT; DRUG TARGETING; INSULIN DEPENDENT DIABETES MELLITUS; LONGEVITY; MITOCHONDRION; OXIDATIVE STRESS; PATIENT CARE; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; OXIDATIVE STRESS;

EID: 79551714674     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010362904     Document Type: Review

References (450)

1. Development OfEC-oa. OECD Health Data 2009. www.ecosante.org/oecd.htm. Accessed December 28, 2009.
2. Maiese K., Chong ZZ, Shang YC Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem. 2007 ; 14: 1729-1738.
3. Maiese K., Morhan SD, Chong ZZ Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res. 2007 ; 4: 63-71. (Pubitemid 46280293)
4. Chan JC, Malik V., Jia W., et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009 ; 301: 2129-2140.
5. Rebecchi KR, Wenke JL, Go EP, Desaire H. Label-free quantitation: a new glycoproteomics approach. J Am Soc Mass Spectrom. 2009 ; 20: 1048-1059.
6. Dabelea D., Bell RA, D'Agostino RB Jr, et al. Incidence of diabetes in youth in the United States. JAMA. 2007 ; 297: 2716-2724.
7. Harris MI, Eastman RC Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes Metab Res Rev. 2000 ; 16: 230-236.
8. Maiese K. Diabetic stress: new triumphs and challenges to maintain vascular longevity. Expert Rev Cardiovasc Ther. 2008 ; 6: 281-284.
9. Daneman D. Type 1 diabetes. Lancet. 2006 ; 367: 847-858.
10. Bonner-Weir S. Life and death of the pancreatic beta cells. Trends Endocrinol Metab. 2000 ; 11: 375-378.
11. Awata T., Kurihara S., Kikuchi C., et al. Evidence for association between the class I subset of the insulin gene minisatellite (IDDM2 locus) and IDDM in the Japanese population. Diabetes. 1997 ; 46: 1637-1642.
12. Baisch JM, Weeks T., Giles R., Hoover M., Stastny P., Capra JD Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. N Engl J Med. 1990 ; 322: 1836-1841.
13. Todd JA, Bell JI, McDevitt HO HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature. 1987 ; 329: 599-604.
14. Lund T., O'Reilly L., Hutchings P., et al. Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A beta-chain or normal I-E alpha-chain. Nature. 1990 ; 345: 727-729.
15. Permutt MA, Wasson J., Cox N. Genetic epidemiology of diabetes. J Clin Invest. 2005 ; 115: 1431-1439.
16. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI Insulin resistance and risk for stroke. Neurology. 2002 ; 59: 809-815.
17. Orchard TJ, Olson JC, Erbey JR, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2003 ; 26: 1374-1379.
18. Pietropaolo M., Barinas-Mitchell E., Pietropaolo SL, Kuller LH, Trucco M. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes. 2000 ; 49: 32-38.
19. Bottino R., Trucco M. Multifaceted therapeutic approaches for a multigenic disease. Diabetes. 2005 ; 54 (suppl 2). S79 - S86.
20. Davies JL, Kawaguchi Y., Bennett ST, et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature. 1994 ; 371: 130-136.
21. Kyvik KO, Green A., Beck-Nielsen H. Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. BMJ. 1995 ; 311: 913-917.
22. Melanitou E. The autoimmune contrivance: genetics in the mouse model. Clin Immunol. 2005 ; 117: 195-206.
23. Redondo MJ, Yu L., Hawa M., et al. Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia. 2001 ; 44: 354-362.
24. Luppi P., Rossiello MR, Faas S., Trucco M. Genetic background and environment contribute synergistically to the onset of autoimmune diseases. J Mol Med. 1995 ; 73: 381-393.
25. Del Prato S., Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res. 2004 ; 36: 775-781.
26. Hao J., Shen W., Tian C., et al. Mitochondrial nutrients improve immune dysfunction in the type 2 diabetic Goto-Kakizaki rats. J Cell Mol Med. 2009 ; 13: 701-711.
27. Morley JE Diabetes, sarcopenia, and frailty. Clin Geriatr Med. 2008 ; 24: 455-469, vi.
28. McIntyre RS, Rasgon NL, Kemp DE, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep. 2009 ; 9: 51-59.
29. Wu SY, Wang GF, Liu ZQ, et al. Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Acta Pharmacol Sin. 2009 ; 30: 202-208.
30. Guarnieri G., Zanetti M., Vinci P., Cattin MR, Barazzoni R. Insulin resistance in chronic uremia. J Ren Nutr. 2009 ; 19: 20-24.
31. Aso Y., Suganuma R., Wakabayashi S., et al. Anemia is associated with an elevated serum level of high-molecular-weight adiponectin in patients with type 2 diabetes independently of renal dysfunction. Transl Res. 2009 ; 154: 175-182.
32. Gossai D., Lau-Cam CA The effects of taurine, taurine homologs and hypotaurine on cell and membrane antioxidative system alterations caused by type 2 diabetes in rat erythrocytes. Adv Exp Med Biol. 2009 ; 643: 359-368.
33. Singh DK, Winocour P., Farrington K. Erythropoietic stress and anemia in diabetes mellitus. Nat Rev Endocrinol. 2009 ; 5: 204-210.
34. Maiese K. Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus. Biomed Pharmacother. 2008 ; 62: 218-232.
35. Maiese K., Chong Z., Li F. Reducing oxidative stress and enhancing neurovascular longevity during diabetes mellitus. In: Neurovascular Medicine: Pursuing Cellular Longevity for Healthy Aging. Maiese K, ed. New York, NY: Oxford University Press ; 2009: 540-564.
36. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA. 2007 ; 298: 765-775.
37. Kuhad A., Bishnoi M., Tiwari V., Chopra K. Suppression of NF-kappabeta signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. Pharmacol Biochem Behav. 2009 ; 92: 251-259.
38. Ott A., Stolk RP, van Harskamp F., Pols HA, Hofman A., Breteler MM Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999 ; 53: 1937-1942.
39. Schnaider Beeri M., Goldbourt U., Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004 ; 63: 1902-1907.
40. Xu WL, Qiu CX, Wahlin A., Winblad B., Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology. 2004 ; 63: 1181-1186.
41. Beeri MS, Silverman JM, Davis KL, et al. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci. 2005 ; 60: 471-475.
42. Maiese K., Chong ZZ, Hou J., Shang YC New strategies for Alzheimer's disease and cognitive impairment. Oxid Med Cell Longev. 2009 ; 2: 279-290.
43. Steen E., Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes ? J Alzheimers Dis. 2005 ; 7: 63-80.
44. Chong ZZ, Li F., Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol. 2005 ; 75: 207-246.
45. Chong ZZ, Li F., Maiese K. Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res Brain Res Rev. 2005 ; 49: 1-21.
46. Maiese K., Holloway HH, Larson DM, Soncrant TT Effect of acute and chronic arecoline treatment on cerebral metabolism and blood flow in the conscious rat. Brain Res. 1994 ; 641: 65-75.
47. Kim HS, Lim JY, Sul D., et al. Neuroprotective effects of the new diterpene, CBNU06 against beta-amyloid-induced toxicity through the inhibition of NF-kappaB signaling pathway in PC12 cells. Eur J Pharmacol. 2009 ; 622: 25-31.
48. Salminen A., Kaarniranta K. Siglec receptors and hiding plaques in Alzheimer's disease. J Mol Med. 2009 ; 87: 697-701.
49. Chong ZZ, Li F., Maiese K. Attempted cell cycle induction in post-mitotic neurons occurs in early and late apoptotic programs through Rb, E2F1, and caspase 3. Curr Neurovasc Res. 2006 ; 3: 25-39.
50. Lin SH, Chong ZZ, Maiese K. Cell cycle induction in post-mitotic neurons proceeds in concert with the initial phase of programmed cell death in rat. Neurosci Lett. 2001 ; 310: 173-177.
51. Majd S., Zarifkar A., Rastegar K., Takhshid MA Different fibrillar Abeta 1-42 concentrations induce adult hippocampal neurons to reenter various phases of the cell cycle. Brain Res. 2008 ; 1218: 224-229.
52. Chong ZZ, Li F., Maiese K. Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr Neurovasc Res. 2005 ; 2: 387-399.
53. Chong ZZ, Li F., Maiese K. Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cell Signal. 2007 ; 19: 1150-1162.
54. Majd S., Rastegar K., Zarifkar A., Takhshid MA Fibrillar beta-amyloid (Abeta) elevates extracellular Abeta in cultured hippocampal neurons of adult rats. Brain Res. 2007 ; 1185: 321-327.
55. Shang YC, Chong ZZ, Hou J., Maiese K. The forkhead transcription factor FoxO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr Neurovasc Res. 2009 ; 6: 20-31.
56. Bakshi P., Margenthaler E., Laporte V., Crawford F., Mullan M. Novel role of CXCR2 in regulation of gamma-secretase activity. ACS Chem Biol. 2008 ; 3: 777-789.
57. Lu J., Wu DM, Zheng YL, et al. Trace amounts of copper exacerbate beta amyloid-induced neurotoxicity in the cholesterol-fed mice through TNF-mediated inflammatory pathway. Brain Behav Immun. 2009 ; 23: 193-203.
58. Bitner RS, Nikkel AL, Markosyan S., Otte S., Puttfarcken P., Gopalakrishnan M. Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo. Brain Res. 2009 ; 1265: 65-74.
59. Vaisid T., Barnoy S., Kosower NS Calpastatin overexpression attenuates amyloid-beta-peptide toxicity in differentiated PC12 cells. Neuroscience. 2008 ; 156: 921-931.
60. Erol A. Unraveling the molecular mechanisms behind the metabolic basis of sporadic Alzheimer's disease. J Alzheimers Dis. 2009 ; 17: 267-276.
61. Maiese K., Chong ZZ Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol Sci. 2003 ; 24: 228-232.
62. Maiese K., Chong ZZ, Hou J., Shang YC The vitamin nicotinamide: translating nutrition into clinical care. Molecules. 2009 ; 14: 3446-3485.
63. Schubert M., Gautam D., Surjo D., et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A. 2004 ; 101: 3100-3105.
64. Newsholme P., Haber EP, Hirabara SM, et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol. 2007 ; 583 (pt 1). 9-24.
65. Szabo C. Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br J Pharmacol. 2009 ; 156: 713-727.
66. Simone S., Gorin Y., Velagapudi C., Abboud HE, Habib SL Mechanism of oxidative DNA damage in diabetes: tuberin inactivation and downregulation of DNA repair enzyme 8-oxo-7,8-dihydro-2'-deoxyguanosine-DNA glycosylase. Diabetes. 2008 ; 57: 2626-2636.
67. Gaddini L., Villa M., Matteucci A., et al. Early effects of high glucose in retinal tissue cultures renin-angiotensin system-dependent and -independent signaling. Neurobiol Dis. 2009 ; 35: 278-285.
68. Singh DK, Winocour P., Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol. 2008 ; 4: 216-226.
69. Barbosa NB, Oliveira C., Araldi D., Folmer V., Rocha JB, Nogueira CW Acute diphenyl diselenide treatment reduces hyperglycemia but does not change delta-aminolevulinate dehydratase activity in alloxan-induced diabetes in rats. Biol Pharm Bull. 2008 ; 31: 2200-2204.
70. Memisogullari R., Bakan E. Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus. J Diabetes Complications. 2004 ; 18: 193-197.
71. Chattopadhyay M., Walter C., Mata M., Fink DJ Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons. Brain. 2009 ; 132 (pt 4). 879-888.
72. Chong ZZ, Shang YC, Maiese K. Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. Curr Neurovasc Res. 2007 ; 4: 194-204.
73. Lin J., Zheng S., Chen A. Curcumin attenuates the effects of insulin on stimulating hepatic stellate cell activation by interrupting insulin signaling and attenuating oxidative stress. Lab Invest. 2009 ; 89: 1397-1409.
74. Liu W., Liu P., Tao S., et al. Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. Arch Biochem Biophys. 2008 ; 475: 128-134.
75. Shang YC, Chong ZZ, Hou J., Maiese K. FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis. Curr Neurovasc Res. 2009 ; 6: 223-238.
76. Chen H., Li X., Epstein PN MnSOD and catalase transgenes demonstrate that protection of islets from oxidative stress does not alter cytokine toxicity. Diabetes. 2005 ; 54: 1437-1446.
77. Lepore DA, Shinkel TA, Fisicaro N., et al. Enhanced expression of glutathione peroxidase protects islet beta cells from hypoxia-reoxygenation. Xenotransplantation. 2004 ; 11: 53-59.
78. Ribeiro MC, Barbosa NB, de Almeida TM, et al. High-fat diet and hydrochlorothiazide increase oxidative stress in brain of rats. Cell Biochem Funct. 2009 ; 27: 473-478.
79. Rachek LI, Thornley NP, Grishko VI, LeDoux SP, Wilson GL Protection of INS-1 cells from free fatty acid-induced apoptosis by targeting hOGG1 to mitochondria. Diabetes. 2006 ; 55: 1022-1028.
80. Haber CA, Lam TK, Yu Z., et al. N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress. Am J Physiol Endocrinol Metab. 2003 ; 285: E744 - E753.
81. Maiese K. Marking the onset of oxidative stress: biomarkers and novel strategies. Oxid Med Cell Longev. 2009 ; 2: 1.
82. Maiese K., Hou J., Chong ZZ, Shang YC Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology. Scientific World Journal. 2009 ; 9: 1072-1104.
83. Maiese K., Chong ZZ, Hou J., Shang YC Erythropoietin and oxidative stress. Curr Neurovasc Res. 2008 ; 5: 125-142.
84. Ihara Y., Toyokuni S., Uchida K., et al. Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes. 1999 ; 48: 927-932.
85. Ceriello A., dello Russo P., Amstad P., Cerutti P. High glucose induces antioxidant enzymes in human endothelial cells in culture: evidence linking hyperglycemia and oxidative stress. Diabetes. 1996 ; 45: 471-477.
86. Yano M., Hasegawa G., Ishii M., et al. Short-term exposure of high glucose concentration induces generation of reactive oxygen species in endothelial cells: implication for the oxidative stress associated with postprandial hyperglycemia. Redox Rep. 2004 ; 9: 111-116.
87. Monnier L., Mas E., Ginet C., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006 ; 295: 1681-1687.
88. De Felice FG, Velasco PT, Lambert MP, et al. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 2007 ; 282: 11590-11601.
89. Lin SH, Maiese K. The metabotropic glutamate receptor system protects against ischemic free radical programmed cell death in rat brain endothelial cells. J Cereb Blood Flow Metab. 2001 ; 21: 262-275.
90. Nomoto M., Miyata M., Yin S., et al. Bile acid-induced elevated oxidative stress in the absence of farnesoid X receptor. Biol Pharm Bull. 2009 ; 32: 172-178.
91. Walsh KB, Toledo AH, Rivera-Chavez FA, Lopez-Neblina F., Toledo-Pereyra LH Inflammatory mediators of liver ischemia-reperfusion injury. Exp Clin Transplant. 2009 ; 7: 78-93.
92. Escobar J., Pereda J., Arduini A., et al. Cross-talk between oxidative stress and pro-inflammatory cytokines in acute pancreatitis: a key role for protein phosphatases. Curr Pharm Des. 2009 ; 15: 3027-3042.
93. Hammoud DA, Hoffman JM, Pomper MG Molecular neuroimaging: from conventional to emerging techniques. Radiology. 2007 ; 245: 21-42.
94. Swan GE, Lessov-Schlaggar CN The effects of tobacco smoke and nicotine on cognition and the brain. Neuropsychol Rev. 2007 ; 17: 259-273.
95. Campos-Esparza MR, Sanchez-Gomez MV, Matute C. Molecular mechanisms of neuroprotection by two natural antioxidant polyphenols. Cell Calcium. 2009 ; 45: 358-368.
96. Chong ZZ, Li F., Maiese K. Group I metabotropic receptor neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and beta-catenin during oxidative stress. Curr Neurovasc Res. 2006 ; 3: 107-117.
97. He Z., Lu Q., Xu X., Huang L., Chen J., Guo L. DDPH ameliorated oxygen and glucose deprivation-induced injury in rat hippocampal neurons via interrupting Ca2+ overload and glutamate release. Eur J Pharmacol. 2009 ; 603: 50-55.
98. Lehtinen MK, Tegelberg S., Schipper H., et al. Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1. J Neurosci. 2009 ; 29: 5910-5915.
99. Ye J., Han Y., Wang C., Yu W. Cytoprotective effect of polypeptide from Chlamys farreri on neuroblastoma (SH-SY5Y) cells following HO exposure involves scavenging ROS and inhibition JNK phosphorylation. J Neurochem. 2009 ; 111: 441-451.
100. Anderson DW, Bradbury KA, Schneider JS Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. Eur J Neurosci. 2008 ; 28: 610-617.
101. Morissette M., Al Sweidi S., Callier S., Di Paolo T. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol Cell Endocrinol. 2008 ; 290: 60-69.
102. Morissette M., Le Saux M., D'Astous M., et al. Contribution of estrogen receptors alpha and beta to the effects of estradiol in the brain. J Steroid Biochem Mol Biol. 2008 ; 108: 327-338.
103. Rodriguez-Blanco J., Martin V., Herrera F., Garcia-Santos G., Antolin I., Rodriguez C. Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine. J Neurochem. 2008 ; 107: 127-140.
104. Sales Santos I., da Rocha Tomé A., Saldanha G., Ferreira P., Militão G., de Freitas R. Oxidative stress in the hippocampus during experimental seizures can be ameliorated with the antioxidant ascorbic acid. Oxid Med Cell Longev. 2009 ; 2: 23-30.
105. Maiese K., Chong ZZ, Shang YC, Hou J. Therapeutic promise and principles: metabotropic glutamate receptors. Oxid Med Cell Longev. 2008 ; 1: 1-14.
106. Probst-Hensch NM, Imboden M., Felber Dietrich D., et al. Glutathione S-transferase polymorphisms, passive smoking, obesity, and heart rate variability in nonsmokers. Environ Health Perspect. 2008 ; 116: 1494-1499.
107. Yemisci M., Gursoy-Ozdemir Y., Vural A., Can A., Topalkara K., Dalkara T. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat Med. 2009 ; 15: 1031-1037.
108. Fatma N., Kubo E., Toris CB, Stamer WD, Camras CB, Singh DP PRDX6 attenuates oxidative stress- and TGFbeta-induced abnormalities of human trabecular meshwork cells. Free Radic Res. 2009 ; 43: 783-795.
109. Gomes P., Simão S., Silva E., et al. Aging increases oxidative stress and renal expression of oxidant and antioxidant enzymes that are associated with an increased trend in systolic blood pressure. Oxid Med Cell Longev. 2009 ; 2: 19-26.
110. Pedersen MO, Jensen R., Pedersen DS, et al. Metallothionein-I+II in neuroprotection. Biofactors. 2009 ; 35: 315-325.
111. Chuang HH, Lin S. Oxidative challenges sensitize the capsaicin receptor by covalent cysteine modification. Proc Natl Acad Sci U S A. 2009 ; 106: 20097-20102.
112. Astiz M., de Alaniz MJ, Marra CA Effect of pesticides on cell survival in liver and brain rat tissues. Ecotoxicol Environ Saf. 2009 ; 72: 2025-2032.
113. Slotkin TA, Seidler FJ Protein kinase C is a target for diverse developmental neurotoxicants: transcriptional responses to chlorpyrifos, diazinon, dieldrin and divalent nickel in PC12 cells. Brain Res. 2009 ; 1263: 23-32.
114. Hamden K., Carreau S., Jamoussi K., et al. 1Alpha,25 dihydroxyvitamin D3: therapeutic and preventive effects against oxidative stress, hepatic, pancreatic and renal injury in alloxan-induced diabetes in rats. J Nutr Sci Vitaminol (Tokyo). 2009 ; 55: 215-222.
115. Regulska M., Leskiewicz M., Budziszewska B., et al. Inhibitory effects of 1,25-dihydroxyvitamin D and its low-calcemic analogues on staurosporine-induced apoptosis. Pharmacol Rep. 2007 ; 59: 393-401.
116. Li F., Chong ZZ, Maiese K. Cell life versus cell longevity: the mysteries surrounding the NAD(+) precursor nicotinamide. Curr Med Chem. 2006 ; 13: 883-895.
117. Li J., Wang H., Rosenberg PA. Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes. J Neurosci Res. 2009 ; 87: 1997-2005.
118. Ozsoy N., Candoken E., Akev N. Implications for degenerative disorders: antioxidative activity, total phenols, flavonoids, ascorbic acid, β-carotene, a-tocopherol in aloe vera. Oxid Med Cell Longev. 2009 ; 2: 99-106.
119. Then SM, Mazlan M., Mat Top G., Wan Ngah WZ Is vitamin E toxic to neuron cells ? Cell Mol Neurobiol. 2009 ; 29: 485-496.
120. El-Mir MY, Detaille D., R-Villanueva G., et al. Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci. 2008 ; 34: 77-87.
121. Kui L., Weiwei Z., Ling L., et al. Ghrelin inhibits apoptosis induced by high glucose and sodium palmitate in adult rat cardiomyocytes through the PI3K-Akt signaling pathway. Regul Pept. 2009 ; 155: 62-69.
122. Head BP, Patel HH, Niesman IR, Drummond JC, Roth DM, Patel PM Inhibition of p75 neurotrophin receptor attenuates isoflurane-mediated neuronal apoptosis in the neonatal central nervous system. Anesthesiology. 2009 ; 110: 813-825.
123. Han Z., Xiao MJ, Shao B., Zheng RY, Yang GY, Jin K. Attenuation of ischemia-induced rat brain injury by 2-(-2-benzofuranyl)-2-imidazoline, a high selectivity ligand for imidazoline I(2) receptors. Neurol Res. 2009 ; 31: 390-395.
124. Maiese K. From the bench to the bedside: the molecular management of cerebral ischemia. Clin Neuropharm. 1998 ; 21: 1-7.
125. Maiese K., Pek L., Berger SB, Reis DJ Reduction in focal cerebral ischemia by agents acting at imidazole receptors. J Cereb Blood Flow Metab. 1992 ; 12: 53-63.
126. Nakka VP, Gusain A., Mehta SL, Raghubir R. Molecular mechanisms of apoptosis in cerebral ischemia: multiple neuroprotective opportunities. Mol Neurobiol. 2008 ; 37: 7-38.
127. Cardoso L., Herman BC, Verborgt O., Laudier D., Majeska RJ, Schaffler MB Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res. 2009 ; 24: 597-605.
128. Arboleda G., Morales LC, Benitez B., Arboleda H. Regulation of ceramide-induced neuronal death: cell metabolism meets neurodegeneration. Brain Res Rev. 2009 ; 59: 333-346.
129. Maiese K., Vincent AM Critical temporal modulation of neuronal programmed cell injury. Cell Mol Neurobiol. 2000 ; 20: 383-400. 130. Zhong J., Zheng W., Huang L., et al. PrP106-126 amide causes the semi-penetrated poration in the supported lipid bilayers. Biochim Biophys Acta. 2007 ; 1768: 1420-1429.
130. Burgos-Ramos E., Puebla-Jimenez L., Arilla-Ferreiro E. Minocycline provides protection against beta-amyloid(25-35)-induced alterations of the somatostatin signaling pathway in the rat temporal cortex. Neuroscience. 2008 ; 154: 1458-1466.
131. Burgos-Ramos E., Puebla-Jimenez L., Arilla-Ferreiro E. Minocycline prevents Abeta(25-35)-induced reduction of somatostatin and neprilysin content in rat temporal cortex. Life Sci. 2009 ; 84: 205-210.
132. Casoli T., Di Stefano G., Giorgetti B., et al. Release of beta-amyloid from high-density platelets: implications for Alzheimer's disease pathology. Ann N Y Acad Sci. 2007 ; 1096: 170-178.
133. Kelley BJ, Knopman DS Alternative medicine and Alzheimer disease. Neurologist. 2008 ; 14: 299-306.
134. Liang WS, Dunckley T., Beach TG, et al. Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics. 2008 ; 33: 240-256.
135. Verdaguer E., Susana Gde A., Clemens A., Pallas M., Camins A. Implication of the transcription factor E2F-1 in the modulation of neuronal apoptosis. Biomed Pharmacother. 2007 ; 61: 390-399.
136. Sommer C. Neuronal plasticity after ischemic preconditioning and TIA-like preconditioning ischemic periods. Acta Neuropathol. 2009 ; 117: 511-523.
137. Braga M., Sinha Hikim AP, Datta S., et al. Involvement of oxidative stress and caspase 2-mediated intrinsic pathway signaling in age-related increase in muscle cell apoptosis in mice. Apoptosis. 2008 ; 13: 822-832.
138. Maiese K., Chong ZZ, Kang J. Transformation into treatment: novel therapeutics that begin within the cell. In: Neuronal and Vascular Plasticity: Elucidating Basic Cellular Mechanisms for Future Therapeutic Discovery. Maiese K, ed. Norwell, Mass: Kluwer Academic ; 2003: 1-26.
139. Gross J., Machulik A., Amarjargal N., et al. Expression of apoptosis-related genes in the organ of Corti, modiolus and stria vascularis of newborn rats. Brain Res. 2007 ; 1162: 56-68.
140. Maiese K., Ahmad I., TenBroeke M., Gallant J. Metabotropic glutamate receptor subtypes independently modulate neuronal intracellular calcium. J Neurosci Res. 1999 ; 55: 472-485.
141. Maiese K., Vincent AM Membrane asymmetry and DNA degradation: functionally distinct determinants of neuronal programmed cell death. J Neurosci Res. 2000 ; 59: 568-580.
142. Dombroski D., Balasubramanian K., Schroit AJ Phosphatidylserine expression on cell surfaces promotes antibody-dependent aggregation and thrombosis in beta2-glycoprotein I-immune mice. J Autoimmun. 2000 ; 14: 221-229.
143. Jessel R., Haertel S., Socaciu C., Tykhonova S., Diehl HA Kinetics of apoptotic markers in exogeneously induced apoptosis of EL4 cells. J Cell Mol Med. 2002 ; 6: 82-92.
144. Kang JQ, Chong ZZ, Maiese K. Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol Pharmacol. 2003 ; 64: 557-569.
145. Maiese K., Vincent A., Lin SH, Shaw T. Group I and Group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection. J Neurosci Res. 2000 ; 62: 257-272.
146. Mari C., Karabiyikoglu M., Goris ML, Tait JF, Yenari MA, Blankenberg FG Detection of focal hypoxic-ischemic injury and neuronal stress in a rodent model of unilateral MCA occlusion/ reperfusion using radiolabeled annexin V. Eur J Nucl Med Mol Imaging. 2004 ; 31: 733-739.
147. Maiese K. The dynamics of cellular injury: transformation into neuronal and vascular protection. Histol Histopathol. 2001 ; 16: 633-644. (Pubitemid 32297661)
148. Vincent AM, Maiese K. Direct temporal analysis of apoptosis induction in living adherent neurons. J Histochem Cytochem. 1999 ; 47: 661-672.
149. Chong ZZ, Lin SH, Kang JQ, Maiese K. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J Neurosci Res. 2003 ; 71: 659-669.
150. Chong ZZ, Lin SH, Kang JQ, Maiese K. The tyrosine phosphatase SHP2 modulates MAP kinase p38 and caspase 1 and 3 to foster neuronal survival. Cell Mol Neurobiol. 2003 ; 23: 561-578.
151. Maiese K., Boccone L. Neuroprotection by peptide growth factors against anoxia and nitric oxide toxicity requires modulation of protein kinase C. J Cereb Blood Flow Metab. 1995 ; 15: 440-449.
152. Maiese K., Boniece IR, Skurat K., Wagner JA Protein kinases modulate the sensitivity of hippocampal neurons to nitric oxide toxicity and anoxia. J Neurosci Res. 1993 ; 36: 77-87.
153. Maiese K., TenBroeke M., Kue I. Neuroprotection of lubeluzole is mediated through the signal transduction pathways of nitric oxide. J Neurochem. 1997 ; 68: 710-714.
154. Leytin V., Allen DJ, Mykhaylov S., Lyubimov E., Freedman J. Thrombin-triggered platelet apoptosis. J Thromb Haemost. 2006 ; 4: 2656-2663.
155. Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol Rev. 2009 ; 228: 149-169.
156. Maiese K., Chong ZZ, Shang YC, Hou J. A "FOXO" in sight: targeting Foxo proteins from conception to cancer. Med Res Rev. 2009 ; 29: 395-418.
157. Chong ZZ, Li F., Maiese K. The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med. 2007 ; 19: 263-272.
158. Dello Russo C., Lisi L., Tringali G., Navarra P. Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem Pharmacol. 2009 ; 78: 1242-1251.
159. Lee SJ, Cho KS, Koh JY Oxidative injury triggers autophagy in astrocytes: the role of endogenous zinc. Glia. 2009 ; 57: 1351-1361.
160. Martin I., Andres CR, Vedrine S., et al. Effect of the oligodendrocyte myelin glycoprotein (OMgp) on the expansion and neuronal differentiation of rat neural stem cells. Brain Res. 2009 ; 1284: 22-30.
161. Geijtenbeek TB, Gringhuis SI Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol. 2009 ; 9: 465-479.
162. Williams R., Dhillon NK, Hegde ST, et al. Proinflammatory cytokines and HIV-1 synergistically enhance CXCL10 expression in human astrocytes. Glia. 2009 ; 57: 734-743.
163. Zhao L., Ma W., Fariss RN, Wong WT Retinal vascular repair and neovascularization are not dependent on CX3CR1 signaling in a model of ischemic retinopathy. Exp Eye Res. 2009 ; 88: 1004-1013.
164. Dringen R. Oxidative and antioxidative potential of brain microglial cells. Antioxid Redox Signal. 2005 ; 7: 1223-1233.
165. Maiese K., Chong ZZ Insights into oxidative stress and potential novel therapeutic targets for Alzheimer disease. Restor Neurol Neurosci. 2004 ; 22: 87-104.
166. Sankarapandi S., Zweier JL, Mukherjee G., Quinn MT, Huso DL Measurement and characterization of superoxide generation in microglial cells: evidence for an NADPH oxidase-dependent pathway. Arch Biochem Biophys. 1998 ; 353: 312-321.
167. Denes A., Ferenczi S., Halasz J., Kornyei Z., Kovacs KJ Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab. 2008 ; 28: 1707-1721.
168. Wu Y., Peng H., Cui M., Whitney NP, Huang Y., Zheng JC CXCL12 increases human neural progenitor cell proliferation through Akt-1/FOXO3a signaling pathway. J Neurochem. 2009 ; 109: 1157-1167.
169. Chong ZZ, Kang JQ, Maiese K. Metabotropic glutamate receptors promote neuronal and vascular plasticity through novel intracellular pathways. Histol Histopathol. 2003 ; 18: 173-189.
170. Kang JQ, Chong ZZ, Maiese K. Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. J Neurosci Res. 2003 ; 74: 37-51.
171. Mallat M., Marin-Teva JL, Cheret C. Phagocytosis in the developing CNS: more than clearing the corpses. Curr Opin Neurobiol. 2005 ; 15: 101-107.
172. Chong ZZ, Kang J., Li F., Maiese K. mGluRI targets microglial activation and selectively prevents neuronal cell engulfment through akt and caspase dependent pathways. Curr Neurovasc Res. 2005 ; 2: 197-211.
173. Li F., Chong ZZ, Maiese K. Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factorkappaB. Curr Neurovasc Res. 2006 ; 3: 187-201.
174. Li F., Chong ZZ, Maiese K. Winding through the WNT pathway during cellular development and demise. Histol Histopathol. 2006 ; 21: 103-124.
175. He XL, Wang YH, Gao M., Li XX, Zhang TT, Du GH Baicalein protects rat brain mitochondria against chronic cerebral hypoperfusion-induced oxidative damage. Brain Res. 2009 ; 1249: 212-221.
176. Maiese K., Chong ZZ, Shang YC, Hou J. Rogue proliferation versus restorative protection: where do we draw the line for Wnt and forkhead signaling ? Expert Opin Ther Targets. 2008 ; 12: 905-916.
177. Plecita-Hlavata L., Lessard M., Santorova J., Bewersdorf J., Jezek P. Mitochondrial oxidative phosphorylation and energetic status are reflected by morphology of mitochondrial network in INS-1E and HEP-G2 cells viewed by 4Pi microscopy. Biochim Biophys Acta. 2008 ; 1777: 834-846.
178. Di Lisa F., Menabo R., Canton M., Barile M., Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem. 2001 ; 276: 2571-2575.
179. Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab. 2003 ; 23: 320-330.
180. Lin SH, Vincent A., Shaw T., Maynard KI, Maiese K. Prevention of nitric oxide-induced neuronal injury through the modulation of independent pathways of programmed cell death. J Cereb Blood Flow Metab. 2000 ; 20: 1380-1391.
181. Kelley DE, He J., Menshikova EV, Ritov VB Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002 ; 51: 2944-2950.
182. Choo HJ, Kim JH, Kwon OB, et al. Mitochondria are impaired in the adipocytes of type 2 diabetic mice. Diabetologia. 2006 ; 49: 784-791.
183. Speese SD, Budnik V. Wnts: up-and-coming at the synapse. Trends Neurosci. 2007 ; 30: 268-275.
184. Espada J., Calvo MB, Diaz-Prado S., Medina V. Wnt signalling and cancer stem cells. Clin Transl Oncol. 2009 ; 11: 411-427.
185. Jozwiak J., Kotulska K., Grajkowska W., et al. Upregulation of the WNT pathway in tuberous sclerosis-associated subependymal giant cell astrocytomas. Brain Dev. 2007 ; 29: 273-280.
186. Jozwiak J., Wlodarski P. Hamartin and tuberin modulate gene transcription via beta-catenin. J Neurooncol. 2006 ; 79: 229-234.
187. Kikuchi A., Yamamoto H., Sato A. Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol. 2009 ; 19: 119-129.
188. Lee JH, Lee EO, Kang JL, Chong YH Concomitant degradation of beta-catenin and GSK-3 beta potently contributes to glutamate-induced neurotoxicity in rat hippocampal slice cultures. J Neurochem. 2008 ; 106: 1066-1077.
189. Luo JM, Dai CF, Lin SY, Huang PQ Asymmetric syntheses and Wnt signal inhibitory activity of melleumin A and four analogues of melleumins A and B. Chem Asian J. 2009 ; 4: 328-335.
190. Maiese K., Hou J., Chong ZZ, Shang YC A fork in the path: developing therapeutic inroads with FoxO proteins. Oxid Med Cell Longev. 2009 ; 2: 119-126.
191. Maiese K., Li F., Chong ZZ, Shang YC The Wnt signaling pathway: aging gracefully as a protectionist ? Pharmacol Ther. 2008 ; 118: 58-81.
192. Mercado-Gomez O., Hernandez-Fonseca K., Villavicencio-Queijeiro A., Massieu L., Chimal-Monroy J., Arias C. Inhibition of Wnt and PI3K signaling modulates GSK-3beta activity and induces morphological changes in cortical neurons: role of tau phosphorylation. Neurochem Res. 2008 ; 33: 1599-1609.
193. Muruganandan S., Roman AA, Sinal CJ Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci. 2009 ; 66: 236-253.
194. Sutton LP, Honardoust D., Mouyal J., Rajakumar N., Rushlow WJ Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3. J Neurochem. 2007 ; 102: 153-169.
195. Vettor R., Milan G., Franzin C., et al. The origin of intermuscular adipose tissue and its pathophysiological implications [published online ahead of print September 8, 2009 ]. Am J Physiol Endocrinol Metab.
196. Wang Z., Havasi A., Gall JM, Mao H., Schwartz JH, Borkan SC Beta-catenin promotes survival of renal epithelial cells by inhibiting Bax. J Am Soc Nephrol. 2009 ; 20: 1919-1928.
197. Wilusz M., Majka M. Role of the Wnt/beta-catenin network in regulating hematopoiesis. Arch Immunol Ther Exp (Warsz). 2008 ; 56: 257-266.
198. Grant SF, Thorleifsson G., Reynisdottir I., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006 ; 38: 320-323.
199. Lehman DM, Hunt KJ, Leach RJ, et al. Haplotypes of transcription factor 7-like 2 (TCF7L2) gene and its upstream region are associated with type 2 diabetes and age of onset in Mexican Americans. Diabetes. 2007 ; 56: 389-393.
200. Scott LJ, Bonnycastle LL, Willer CJ, et al. Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes. 2006 ; 55: 2649-2653.
201. Guo YF, Xiong DH, Shen H., et al. Polymorphisms of the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with obesity phenotypes in a large family-based association study. J Med Genet. 2006 ; 43: 798-803.
202. Kanazawa A., Tsukada S., Sekine A., et al. Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am J Hum Genet. 2004 ; 75: 832-843.
203. Mani A., Radhakrishnan J., Wang H., et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science. 2007 ; 315: 1278-1282.
204. Al-Aly Z., Shao JS, Lai CF, et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol. 2007 ; 27: 2589-2596.
205. Wright WS, Longo KA, Dolinsky VW, et al. Wnt10b inhibits obesity in ob/ob and Agouti mice. Diabetes. 2007 ; 56: 295-303.
206. Lin CL, Wang JY, Huang YT, Kuo YH, Surendran K., Wang FS Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol. 2006 ; 17: 2812-2820.
207. Aslanidi G., Kroutov V., Philipsberg G., et al. Ectopic expression of Wnt10b decreases adiposity and improves glucose homeostasis in obese rats. Am J Physiol Endocrinol Metab. 2007 ; 293: E726 - E736.
208. Maiese K., Chong ZZ, Li F., Shang YC Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol. 2008 ; 85: 194-213.
209. Maiese K., Chong ZZ, Shang YC Raves and risks for erythropoietin. Cytokine Growth Factor Rev. 2008 ; 19: 145-155.
210. Gayer CP, Chaturvedi LS, Wang S., Craig DH, Flanigan T., Basson MD Strain-induced proliferation requires the phosphatidylinositol 3-kinase/AKT/glycogen synthase kinase pathway. J Biol Chem. 2009 ; 284: 2001-2011.
211. An J., Zhang C., Polavarapu R., Zhang X., Yepes M. Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. Blood. 2008 ; 112: 2787-2794.
212. Slaets H., Dumont D., Vanderlocht J., et al. Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3. Proteomics. 2008 ; 8: 1237-1247.
213. Dreixler JC, Hemmert JW, Shenoy SK, et al. The role of Akt/ protein kinase B subtypes in retinal ischemic preconditioning. Exp Eye Res. 2009 ; 88: 512-521.
214. Anitha M., Gondha C., Sutliff R., et al. GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway. J Clin Invest. 2006 ; 116: 344-356.
215. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002 ; 106: 2973-2979.
216. Burgos-Ramos E., Martos-Moreno GA, Lopez MG, et al. The N-terminal tripeptide of insulin-like growth factor-I protects against beta-amyloid-induced somatostatin depletion by calcium and glycogen synthase kinase 3 beta modulation. J Neurochem. 2009 ; 109: 360-370.
217. Tamagno E., Guglielmotto M., Giliberto L., et al. JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1. Neurobiol Aging. 2009 ; 30: 1563-1573.
218. Kim KH, Oudit GY, Backx PH Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther. 2008 ; 324: 160-169.
219. Tajes M., Yeste-Velasco M., Zhu X., et al. Activation of Akt by lithium: pro-survival pathways in aging. Mech Ageing Dev. 2009 ; 130: 253-261.
220. Chong ZZ, Kang JQ, Maiese K. Akt1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-x(L) and caspase 1, 3, and 9. Exp Cell Res. 2004 ; 296: 196-207.
221. Chong ZZ, Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol. 2007 ; 150: 839-850.
222. Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol. 2003 ; 138: 1107-1118.
223. Fujiwara M., Izuishi K., Sano T., et al. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J Exp Clin Cancer Res. 2008 ; 27: 76.
224. Chong ZZ, Li F., Maiese K. Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol Histopathol. 2005 ; 20: 299-315.
225. Chong ZZ, Maiese K. Targeting WNT, protein kinase B, and mitochondrial membrane integrity to foster cellular survival in the nervous system. Histol Histopathol. 2004 ; 19: 495-504.
226. Fukumoto S., Hsieh CM, Maemura K., et al. Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem. 2001 ; 276: 17479-17483.
227. Naito AT, Akazawa H., Takano H., et al. Phosphatidylinositol 3-kinase-Akt pathway plays a critical role in early cardiomyogenesis by regulating canonical Wnt signaling. Circ Res. 2005 ; 97: 144-151.
228. Longo KA, Kennell JA, Ochocinska MJ, Ross SE, Wright WS, MacDougald OA Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J Biol Chem. 2002 ; 277: 38239-38244.
229. Su F., Overholtzer M., Besser D., Levine AJ WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev. 2002 ; 16: 46-57.
230. Mirotsou M., Zhang Z., Deb A., et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci U S A. 2007 ; 104: 1643-1648.
231. van de Schans VA, van den Borne SW, Strzelecka AE, et al. Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy. Hypertension. 2007 ; 49: 473-480.
232. Barandon L., Dufourcq P., Costet P., et al. Involvement of FrzA/ sFRP-1 and the Wnt/frizzled pathway in ischemic preconditioning. Circ Res. 2005 ; 96: 1299-1306.
233. DiPalma JR, Thayer WS Use of niacin as a drug. Annu Rev Nutr. 1991 ; 11: 169-187.
234. Rex A., Fink H. Pharmacokinetic aspects of reduced nicotinamide adenine dinucleotide (NADH) in rats. Front Biosci. 2008 ; 13: 3735-3741.
235. Li F., Chong ZZ, Maiese K. Navigating novel mechanisms of cellular plasticity with the NAD+ precursor and nutrient nicotinamide. Front Biosci. 2004 ; 9: 2500-2520.
236. Jackson TM, Rawling JM, Roebuck BD, Kirkland JB Large supplements of nicotinic acid and nicotinamide increase tissue NAD+ and poly(ADP-ribose) levels but do not affect diethylnitrosamineinduced altered hepatic foci in Fischer-344 rats. J Nutr. 1995 ; 125: 1455-1461.
237. Wojcik M., Seidle HF, Bieganowski P., Brenner C. Glutamine-dependent NAD+ synthetase: how a two-domain, three-substrate enzyme avoids waste. J Biol Chem. 2006 ; 281: 33395-33402.
238. Khan JA, Forouhar F., Tao X., Tong L. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets. 2007 ; 11: 695-705.
239. Khan JA, Xiang S., Tong L. Crystal structure of human nicotinamide riboside kinase. Structure. 2007 ; 15: 1005-1013.
240. Depeint F., Bruce WR, Shangari N., Mehta R., O'Brien PJ Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism. Chem Biol Interact. 2006 ; 163: 94-112.
241. Hara N., Yamada K., Shibata T., Osago H., Hashimoto T., Tsuchiya M. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J Biol Chem. 2007 ; 282: 24574-24582.
242. Williams AC, Ramsden DB Pellagra: a clue as to why energy failure causes diseases ? Med Hypotheses. 2007 ; 69: 618-628.
243. Williams AC, Ramsden DB Hydrogen symbioses in evolution and disease. QJM. 2007 ; 100: 451-459.
244. Magni G., Amici A., Emanuelli M., Orsomando G., Raffaelli N., Ruggieri S. Enzymology of NAD+ homeostasis in man. Cell Mol Life Sci. 2004 ; 61: 19-34.
245. Lin SJ, Guarente L. Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr Opin Cell Biol. 2003 ; 15: 241-246.
246. Hageman GJ, Stierum RH Niacin, poly(ADP-ribose) polymerase-1 and genomic stability. Mutat Res. 2001 ; 475: 45-56.
247. Sadanaga-Akiyoshi F., Yao H., Tanuma S., et al. Nicotinamide attenuates focal ischemic brain injury in rats: with special reference to changes in nicotinamide and NAD+ levels in ischemic core and penumbra. Neurochem Res. 2003 ; 28: 1227-1234.
248. Wang J., Zhai Q., Chen Y., et al. A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol. 2005 ; 170: 349-355.
249. Chong ZZ, Lin SH, Maiese K. Nicotinamide modulates mitochondrial membrane potential and cysteine protease activity during cerebral vascular endothelial cell injury. J Vasc Res. 2002 ; 39: 131-147.
250. Maiese K., Lin S., Chong ZZ Elucidating neuronal and vascular injury through the cytoprotective agent nicotinamide. Curr Med Chem Immunol Endocr Metab Agents. 2001 ; 1: 257-267.
251. Chong ZZ, Lin SH, Li F., Maiese K. The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through Akt, Bad, PARP, and mitochondrial associated "anti-apoptotic" pathways. Curr Neurovasc Res. 2005 ; 2: 271-285.
252. Chong ZZ, Lin SH, Maiese K. The NAD+ precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. J Cereb Blood Flow Metab. 2004 ; 24: 728-743.
253. Halestrap AP, Woodfield KY, Connern CP Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J Biol Chem. 1997 ; 272: 3346-3354.
254. La Piana G., Marzulli D., Consalvo MI, Lofrumento NE Cytochrome c-induced cytosolic nicotinamide adenine dinucleotide oxidation, mitochondrial permeability transition, and apoptosis. Arch Biochem Biophys. 2003 ; 410: 201-211.
255. Idelson M., Alper R., Obolensky A., et al. Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. Cell Stem Cell. 2009 ; 5: 396-408.
256. Aoyagi S., Archer TK Nicotinamide uncouples hormone-dependent chromatin remodeling from transcription complex assembly. Mol Cell Biol. 2008 ; 28: 30-39.
257. Bruno V., Battaglia G., Copani A., et al. Activation of class II or III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration. Eur J Neurosci. 1995 ; 7: 1906-1913.
258. Anderson DW, Bradbury KA, Schneider JS Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci. 2006 ; 24: 3174-3182.
259. Feng Y., Paul IA, LeBlanc MH Nicotinamide reduces hypoxic ischemic brain injury in the newborn rat. Brain Res Bull. 2006 ; 69: 117-122.
260. Lin SH, Chong ZZ, Maiese K. Nicotinamide: a nutritional supplement that provides protection against neuronal and vascular injury. J Med Food. 2001 ; 4: 27-38.
261. Slomka M., Zieminska E., Salinska E., Lazarewicz JW Neuroprotective effects of nicotinamide and 1-methylnicotinamide in acute excitotoxicity in vitro. Folia Neuropathol. 2008 ; 46: 69-80.
262. Slomka M., Zieminska E., Lazarewicz J. Nicotinamide and 1-methylnicotinamide reduce homocysteine neurotoxicity in primary cultures of rat cerebellar granule cells. Acta Neurobiol Exp (Wars). 2008 ; 68: 1-9.
263. Ieraci A., Herrera DG Nicotinamide protects against ethanol-induced apoptotic neurodegeneration in the developing mouse brain. PLoS Med. 2006 ; 3: e101.
264. Shen CC, Huang HM, Ou HC, Chen HL, Chen WC, Jeng KC Protective effect of nicotinamide on neuronal cells under oxygen and glucose deprivation and hypoxia/reoxygenation. J Biomed Sci. 2004 ; 11: 472-481.
265. Sonee M., Martens JR, Evers MR, Mukherjee SK The effect of tertiary butylhydroperoxide and nicotinamide on human cortical neurons. Neurotoxicology. 2003 ; 24: 443-448.
266. Kiuchi K., Kondo M., Ueno S., et al. Functional rescue of N-methyl-N-nitrosourea-induced retinopathy by nicotinamide in Sprague-Dawley rats. Curr Eye Res. 2003 ; 26: 355-362.
267. Kiuchi K., Yoshizawa K., Shikata N., Matsumura M., Tsubura A. Nicotinamide prevents N-methyl-N-nitrosourea-induced photoreceptor cell apoptosis in Sprague-Dawley rats and C57BL mice. Exp Eye Res. 2002 ; 74: 383-392.
268. Reber F., Geffarth R., Kasper M., et al. Graded sensitiveness of the various retinal neuron populations on the glyoxal-mediated formation of advanced glycation end products and ways of protection. Graefes Arch Clin Exp Ophthalmol. 2003 ; 241: 213-225.
269. Hoane MR, Gilbert DR, Holland MA, Pierce JL Nicotinamide reduces acute cortical neuronal death and edema in the traumatically injured brain. Neurosci Lett. 2006 ; 408: 35-39.
270. Hoane MR, Kaplan SA, Ellis AL The effects of nicotinamide on apoptosis and blood-brain barrier breakdown following traumatic brain injury. Brain Res. 2006 ; 1125: 185-193.
271. Hoane MR, Pierce JL, Holland MA, Anderson GD Nicotinamide treatment induces behavioral recovery when administered up to 4 hours following cortical contusion injury in the rat. Neuroscience. 2008 ; 154: 861-868.
272. Hoane MR, Pierce JL, Kaufman NA, Beare JE Variation in chronic nicotinamide treatment after traumatic brain injury can alter components of functional recovery independent of histological damage. Oxid Med Cell Longev. 2008 ; 1: 45-52.
273. Holland MA, Tan AA, Smith DC, Hoane MR Nicotinamide treatment provides acute neuroprotection and GFAP regulation following fluid percussion injury. J Neurotrauma. 2008 ; 25: 140-152.
274. Wallis RA, Panizzon KL, Girard JM Traumatic neuroprotection with inhibitors of nitric oxide and ADP-ribosylation. Brain Res. 1996 ; 710: 169-177.
275. Yang J., Klaidman L., Chang M., et al. Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model. Pharmacol Biochem Behav. 2002 ; 73: 901-910.
276. Gupta S., Kaul CL, Sharma SS Neuroprotective effect of combination of poly (ADP-ribose) polymerase inhibitor and antioxidant in middle cerebral artery occlusion induced focal ischemia in rats. Neurol Res. 2004 ; 26: 103-107.
277. Sakakibara Y., Mitha AP, Ayoub IA, Ogilvy CS, Maynard KI Delayed treatment with nicotinamide (vitamin B3) reduces the infarct volume following focal cerebral ischemia in spontaneously hypertensive rats, diabetic and non-diabetic Fischer 344 rats. Brain Res. 2002 ; 931: 68-73.
278. Macleod MR, O'Collins T., Howells DW, Donnan GA Pooling of animal experimental data reveals influence of study design and publication bias. Stroke. 2004 ; 35: 1203-1208.
279. Brewer KL, Hardin JS Neuroprotective effects of nicotinamide after experimental spinal cord injury. Acad Emerg Med. 2004 ; 11: 125-130.
280. Isbir CS, Ak K., Kurtkaya O., et al. Ischemic preconditioning and nicotinamide in spinal cord protection in an experimental model of transient aortic occlusion. Eur J Cardiothorac Surg. 2003 ; 23: 1028-1033.
281. Williams A., Ramsden D. Nicotinamide: a double edged sword. Parkinsonism Relat Disord. 2005 ; 11: 413-420.
282. Williams AC, Cartwright LS, Ramsden DB Parkinson's disease: the first common neurological disease due to auto-intoxication ? QJM. 2005 ; 98: 215-226.
283. Beck H., Plate KH Angiogenesis after cerebral ischemia. Acta Neuropathol. 2009 ; 117: 481-496.
284. Giulumian AD, Meszaros LG, Fuchs LC Endothelin-1-induced contraction of mesenteric small arteries is mediated by ryanodine receptor Ca2+ channels and cyclic ADP-ribose. J Cardiovasc Pharmacol. 2000 ; 36: 758-763.
285. Pietrzak L., Mogielnicki A., Buczko W. Nicotinamide and its metabolite N-methylnicotinamide increase skin vascular permeability in rats. Clin Exp Dermatol. 2009 ; 34: 380-384.
286. Oumouna-Benachour K., Hans CP, Suzuki Y., et al. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factorkappaB nuclear translocation, and foam cell death. Circulation. 2007 ; 115: 2442-2450.
287. Giammona LM, Fuhrken PG, Papoutsakis ET, Miller WM Nicotinamide (vitamin B3) increases the polyploidisation and proplatelet formation of cultured primary human megakaryocytes. Br J Haematol. 2006 ; 135: 554-566.
288. Slominska EM, Yuen A., Osman L., Gebicki J., Yacoub MH, Smolenski RT Cytoprotective effects of nicotinamide derivatives in endothelial cells. Nucleosides Nucleotides Nucleic Acids. 2008 ; 27: 863-866.
289. Mateuszuk L., Khomich TI, Slominska E., et al. Activation of nicotinamide N-methyltrasferase and increased formation of 1-methylnicotinamide (MNA) in atherosclerosis. Pharmacol Rep. 2009 ; 61: 76-85.
290. Vincent AM, Maiese K. Nitric oxide induction of neuronal endonuclease activity in programmed cell death. Exp Cell Res. 1999 ; 246: 290-300.
291. Vincent AM, TenBroeke M., Maiese K. Metabotropic glutamate receptors prevent programmed cell death through the modulation of neuronal endonuclease activity and intracellular pH. Exp Neurol. 1999 ; 155: 79-94.
292. Vincent AM, TenBroeke M., Maiese K. Neuronal intracellular pH directly mediates nitric oxide-induced programmed cell death. J Neurobiol. 1999 ; 40: 171-184.
293. Young GS, Jacobson EL, Kirkland JB Water maze performance in young male Long-Evans rats is inversely affected by dietary intakes of niacin and may be linked to levels of the NAD+ metabolite cADPR. J Nutr. 2007 ; 137: 1050-1057.
294. Reddy S., Bibby NJ, Wu D., Swinney C., Barrow G., Elliott RB A combined casein-free-nicotinamide diet prevents diabetes in the NOD mouse with minimum insulitis. Diabetes Res Clin Pract. 1995 ; 29: 83-92.
295. Hu Y., Wang Y., Wang L., et al. Effects of nicotinamide on prevention and treatment of streptozotocin-induced diabetes mellitus in rats. Chin Med J (Engl). 1996 ; 109: 819-822.
296. Stevens MJ, Li F., Drel VR, et al. Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. J Pharmacol Exp Ther. 2007 ; 320: 458-464.
297. Cresto JC, Fabiano de Bruno LE, Cao GF, et al. The association of acetyl-l-carnitine and nicotinamide remits the experimental diabetes in mice by multiple low-dose streptozotocin. Pancreas. 2006 ; 33: 403-411.
298. Chlopicki S., Swies J., Mogielnicki A., et al. 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. Br J Pharmacol. 2007 ; 152: 230-239.
299. Lee HI, Cho HJ, Han JA, et al. Transient downregulation of protein O-N-acetylglucosaminylation by treatment of high-dose nicotinamide in human cells. Exp Mol Med. 2008 ; 40: 246-253.
300. Tam D., Tam M., Maynard KI Nicotinamide modulates energy utilization and improves functional recovery from ischemia in the in vitro rabbit retina. Ann N Y Acad Sci. 2005 ; 1053: 258-268.
301. Olmos PR, Hodgson MI, Maiz A., et al. Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics. Diabetes Res Clin Pract. 2006 ; 71: 320-333.
302. Crino A., Schiaffini R., Ciampalini P., et al. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2005 ; 18: 749-754.
303. Eto N., Miyata Y., Ohno H., Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant. 2005 ; 20: 1378-1384.
304. Liu HK, Green BD, Flatt PR, McClenaghan NH, McCluskey JT Effects of long-term exposure to nicotinamide and sodium butyrate on growth, viability, and the function of clonal insulin secreting cells. Endocr Res. 2004 ; 30: 61-68.
305. Reddy S., Salari-Lak N., Sandler S. Long-term effects of nicotinamide-induced inhibition of poly(adenosine diphosphate-ribose) polymerase activity in rat pancreatic islets exposed to interleukin-1 beta. Endocrinology. 1995 ; 136: 1907-1912.
306. Zhou SS, Li D., Sun WP, et al. Nicotinamide overload may play a role in the development of type 2 diabetes. World J Gastroenterol. 2009 ; 15: 5674-5684.
307. Gaudineau C., Auclair K. Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. Biochem Biophys Res Commun. 2004 ; 317: 950-956.
308. Maiese K., Chong ZZ, Shang YC " Sly as a FOXO": new paths with Forkhead signaling in the brain. Curr Neurovasc Res. 2007 ; 4: 295-302.
309. Maiese K., Chong ZZ, Shang YC OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med. 2008 ; 14: 219-227.
310. Coffer PJ When less is more: the PI3K pathway as a determinant of tumor response to dietary restriction. Cell Res. 2009 ; 19: 797-799.
311. Jacobsen EA, Ananieva O., Brown ML, Chang Y. Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene. J Immunol. 2006 ; 176: 6831-6838.
312. Maiese K., Chong ZZ, Shang YC, Hou J. Clever cancer strategies with FoxO transcription factors. Cell Cycle. 2008 ; 7: 3829-3839.
313. Maiese K., Chong ZZ, Shang YC, Hou J. FoxO proteins: cunning concepts and considerations for the cardiovascular system. Clin Sci (Lond). 2009 ; 116: 191-203.
314. Clark KL, Halay ED, Lai E., Burley SK Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature. 1993 ; 364: 412-420.
315. Jin C., Marsden I., Chen X., Liao X. Sequence specific collective motions in a winged helix DNA binding domain detected by 15N relaxation NMR. Biochemistry. 1998 ; 37: 6179-6187.
316. Maiese K., Chong Z., Hou J., Shang Y. The "O" class: crafting clinical care with FoxO transcription factors. Adv Exp Med Biol. 2009 ; 665: 242-260.
317. Kaestner KH, Knochel W., Martinez DE Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev. 2000 ; 14: 142-146.
318. Lappas M., Lim R., Riley C., Rice GE, Permezel M. Localisation and expression of FoxO1 proteins in human gestational tissues. Placenta. 2009 ; 30: 256-262.
319. Zheng WH, Kar S., Quirion R. FKHRL1 and its homologs are new targets of nerve growth factor Trk receptor signaling. J Neurochem. 2002 ; 80: 1049-1061.
320. Fei M., Lu M., Wang Y., et al. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med Oncol. 2009 ; 26: 178-185.
321. Lei H., Quelle FW FOXO transcription factors enforce cell cycle checkpoints and promote survival of hematopoietic cells after DNA damage. Mol Cancer Res. 2009 ; 7: 1294-1303.
322. Kikuchi S., Nagai T., Kunitama M., Kirito K., Ozawa K., Komatsu N. Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci. 2007 ; 98: 1949-1958.
323. Nowak K., Killmer K., Gessner C., Lutz W. E2F-1 regulates expression of FOXO1 and FOXO3a. Biochim Biophys Acta. 2007 ; 1769: 244-252.
324. Bouchard C., Lee S., Paulus-Hock V., Loddenkemper C., Eilers M., Schmitt CA FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. Genes Dev. 2007 ; 21: 2775-2787.
325. Bethea CL, Reddy AP, Tokuyama Y., Henderson JA, Lima FB Protective actions of ovarian hormones in the serotonin system of macaques. Front Neuroendocrinol. 2009 ; 30: 212-238.
326. Chong ZZ, Kang JQ, Maiese K. Essential cellular regulatory elements of oxidative stress in early and late phases of apoptosis in the central nervous system. Antioxid Redox Signal. 2004 ; 6: 277-287.
327. Fallarino F., Bianchi R., Orabona C., et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med. 2004 ; 200: 1051-1062.
328. Nakae J., Cao Y., Oki M., et al. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. Diabetes. 2008 ; 57: 563-576.
329. Furuyama T., Yamashita H., Kitayama K., Higami Y., Shimokawa I., Mori N. Effects of aging and caloric restriction on the gene expression of Foxo1, 3, and 4 (FKHR, FKHRL1, and AFX) in the rat skeletal muscles. Microsc Res Tech. 2002 ; 59: 331-334.
330. Puig O., Tjian R. Transcriptional feedback control of insulin receptor by dFOXO/FOXO1. Genes Dev. 2005 ; 19: 2435-2446.
331. Kim JR, Jung HS, Bae SW, et al. Polymorphisms in FOXO gene family and association analysis with BMI. Obesity (Silver Spring). 2006 ; 14: 188-193.
332. Marchetti V., Menghini R., Rizza S., et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes. 2006 ; 55: 2231-2237.
333. Kamagate A., Dong HH Foxo1 integrates insulin signaling to VLDL production. Cell Cycle. 2008 ; 7: 3162-3170.
334. Ni YG, Wang N., Cao DJ, et al. FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci U S A. 2007 ; 104: 20517-20522.
335. Kamei Y., Miura S., Suzuki M., et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem. 2004 ; 279: 41114-41123.
336. Liu CM, Yang Z., Liu CW, et al. Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther. 2007 ; 14: 945-952.
337. Sandri M., Lin J., Handschin C., et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A. 2006 ; 103: 16260-16265.
338. Maiese K., Li F., Chong ZZ Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci. 11 2004 ; 25: 577-583.
339. Charvet C., Alberti I., Luciano F., et al. Proteolytic regulation of Forkhead transcription factor FOXO3a by caspase-3-like proteases. Oncogene. 2003 ; 22: 4557-4568.
340. Porcu M., Chiarugi A. The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to life span extension. Trends Pharmacol Sci. 2005 ; 26: 94-103.
341. Saunders LR, Verdin E. Sirtuins: critical regulators at the cross-roads between cancer and aging. Oncogene. 2007 ; 26: 5489-5504.
342. Taylor DM, Maxwell MM, Luthi-Carter R., Kazantsev AG Biological and potential therapeutic roles of sirtuin deacetylases. Cell Mol Life Sci. 2008 ; 65: 4000-4018.
343. Zschoernig B., Mahlknecht U. SIRTUIN 1: regulating the regulator. Biochem Biophys Res Commun. 2008 ; 376: 251-255.
344. Tang BL, Chua CE SIRT1 and neuronal diseases. Mol Aspects Med. 2008 ; 29: 187-200.
345. Zwaal RF, Schroit AJ Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 1997 ; 89: 1121-1132.
346. Canto C., Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab. 2009 ; 20: 325-331.
347. Balan V., Miller GS, Kaplun L., et al. Life span extension and neuronal cell protection by Drosophila nicotinamidase. J Biol Chem. 2008 ; 283: 27810-27819.
348. Bureau G., Longpre F., Martinoli MG Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res. 2008 ; 86: 403-410.
349. Chong ZZ, Maiese K. Enhanced tolerance against early and late apoptotic oxidative stress in mammalian neurons through nicotinamidase and sirtuin mediated pathways. Curr Neurovasc Res. 2008 ; 5: 159-170.
350. Nemoto S., Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science. 2004 ; 306: 2105-2108.
351. Ferrara N., Rinaldi B., Corbi G., et al. Exercise training promotes SIRT1 activity in aged rats. Rejuvenation Res. 2008 ; 11: 139-150.
352. Motta MC, Divecha N., Lemieux M., et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004 ; 116: 551-563.
353. Lee HI, Jang SY, Kang HT, Hwang ES p53-, SIRT1-, and PARP-1-independent downregulation of p21WAF1 expression in nicotinamide-treated cells. Biochem Biophys Res Commun. 2008 ; 368: 298-304.
354. Jackson MD, Schmidt MT, Oppenheimer NJ, Denu JM Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/ protein deacetylases. J Biol Chem. 2003 ; 278: 50985-50998.
355. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M., Sinclair DA Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem. 2002 ; 277: 45099-45107.
356. Cai AL, Zipfel GJ, Sheline CT Zinc neurotoxicity is dependent on intracellular NAD levels and the sirtuin pathway. Eur J Neurosci. 2006 ; 24: 2169-2176.
357. Kruszewski M., Szumiel I. Sirtuins (histone deacetylases III) in the cellular response to DNA damage-facts and hypotheses. DNA Repair (Amst). 2005 ; 4: 1306-1313.
358. Yoshizaki T., Milne JC, Imamura T., et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol. 2009 ; 29: 1363-1374.
359. Zillikens MC, van Meurs JB, Rivadeneira F., et al. SIRT1 genetic variation is related to BMI and risk of obesity. Diabetes. 2009 ; 58: 2828-2834.
360. Maiese K., Li F., Chong ZZ New avenues of exploration for erythropoietin. JAMA. 2005 ; 293: 90-95.
361. Girgenti MJ, Hunsberger J., Duman CH, Sathyanesan M., Terwilliger R., Newton SS Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biol Psychiatry. 2009 ; 66: 267-274.
362. Ma R., Xiong N., Huang C., et al. Erythropoietin protects PC12 cells from beta-amyloid(25-35)-induced apoptosis via PI3K/Akt signaling pathway. Neuropharmacology. 2009 ; 56: 1027-1034.
363. Sun ZK, Yang HQ, Pan J., et al. Protective effects of erythropoietin on tau phosphorylation induced by beta-amyloid. J Neurosci Res. 2008 ; 86: 3018-3027.
364. McLeod M., Hong M., Mukhida K., Sadi D., Ulalia R., Mendez I. Erythropoietin and GDNF enhance ventral mesencephalic fiber outgrowth and capillary proliferation following neural transplantation in a rodent model of Parkinson's disease. Eur J Neurosci. 2006 ; 24: 361-370.
365. Cuzzocrea S., Mazzon E., di Paola R., et al. Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. Arthritis Rheum. 2005 ; 52: 940-950.
366. Thorne M., Moore CS, Robertson GS Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: effects of darbepoetin alfa on TIMP-1 null and wild-type mice. J Neuroimmunol. 2009 ; 211: 92-100.
367. Sanchez PE, Fares RP, Risso JJ, et al. Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc Natl Acad Sci U S A. 2009 ; 106: 9848-9853.
368. Sanchez PE, Navarro FP, Fares RP, et al. Erythropoietin receptor expression is concordant with erythropoietin but not with common beta chain expression in the rat brain throughout the life span. J Comp Neurol. 2009 ; 514: 403-414.
369. Slotkin TA, Seidler FJ, Fumagalli F. Targeting of neurotrophic factors, their receptors, and signaling pathways in the developmental neurotoxicity of organophosphates in vivo and in vitro. Brain Res Bull. 2008 ; 76: 424-438.
370. van der Kooij MA, Groenendaal F., Kavelaars A., Heijnen CJ, van Bel F. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ ischemia. Brain Res Rev. 2008 ; 59: 22-33.
371. Andreotti F., Agati L., Conti E., et al. Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS). J Thromb Thrombolysis. 2009 ; 28: 489-495.
372. Brunner S., Winogradow J., Huber BC, et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis. FASEB J. 2009 ; 23: 351-361.
373. Incagnoli P., Ramond A., Joyeux-Faure M., Pepin JL, Levy P., Ribuot C. Erythropoietin improved initial resuscitation and increased survival after cardiac arrest in rats. Resuscitation. 2009 ; 80: 696-700.
374. Li CL, Jiang J., Fan YQ, Fu GS, Wang JA, Fan WM Knockout of the tumor necrosis factor a receptor 1 gene can up-regulate erythropoietin receptor during myocardial ischemia-reperfusion injury in mice. Chin Med J (Engl). 2009 ; 122: 566-570.
375. Schlecht-Bauer D., Antier D., Machet MC, Hyvelin JM Short-and long-term cardioprotective effect of darbepoetin-alpha: role of Bcl-2 family proteins [published online ahead of print July 10, 2009 ]. J Cardiovasc Pharmacol.
376. Smith K., Semple D., Bhandari S., Seymour AM Cellular basis of uraemic cardiomyopathy: a role for erythropoietin ? Eur J Heart Fail. 2009 ; 11: 732-738.
377. Timmer SA, De Boer K., Knaapen P., Gotte MJ, Van Rossum AC The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis ? J Card Fail. 2009 ; 15: 353-361.
378. Uitterdijk A., Groenendijk BC, van Der Giessen WJ Stem cell therapy for chronic heart failure. Hellenic J Cardiol. 2009 ; 50: 127-132.
379. Matis GK, Birbilis TA Erythropoietin in spinal cord injury. Eur Spine J. 2009 ; 18: 314-323.
380. Yoo JY, Won YJ, Lee JH, et al. Neuroprotective effects of erythropoietin posttreatment against kainate-induced excitotoxicity in mixed spinal cultures. J Neurosci Res. 2009 ; 87: 150-163.
381. Okutan O., Turkoglu OF, Gok HB, Beskonakli E. Neuroprotective effect of erythropoietin after experimental cold injury-induced vasogenic brain edema in rats. Surg Neurol. 2008 ; 70: 498-502.
382. Karaca M., Odabasoglu F., Kumtepe Y., Albayrak A., Cadirci E., Keles ON Protective effects of erythropoietin on ischemia/reperfusion injury of rat ovary. Eur J Obstet Gynecol Reprod Biol. 2009 ; 144: 157-162.
383. Harder Y., Amon M., Schramm R., et al. Erythropoietin reduces necrosis in critically ischemic myocutaneous tissue by protecting nutritive perfusion in a dose-dependent manner. Surgery. 2009 ; 145: 372-383.
384. Rotter R., Menshykova M., Winkler T., et al. Erythropoietin improves functional and histological recovery of traumatized skeletal muscle tissue. J Orthop Res. 2008 ; 26: 1618-1626.
385. Zhu L., Wang HD, Yu XG, et al. Erythropoietin prevents zinc accumulation and neuronal death after traumatic brain injury in rat hippocampus: in vitro and in vivo studies. Brain Res. 2009 ; 1289: 96-105.
386. Aoshiba K., Onizawa S., Tsuji T., Nagai A. Therapeutic effects of erythropoietin in murine models of endotoxin shock. Crit Care Med. 2009 ; 37: 889-898.
387. Contaldo C., Elsherbiny A., Lindenblatt N., et al. Erythropoietin enhances oxygenation in critically perfused tissue through modulation of nitric oxide synthase. Shock. 2009 ; 31: 599-606.
388. Simon F., Calzia E., Radermacher P., Schelzig H. Beneficial effects of erythropoietin in models of shock and organ failure-nothing is simple and easy. Shock. 2009 ; 31: 220-221.
389. Casals-Pascual C., Idro R., Picot S., Roberts DJ, Newton CR Can erythropoietin be used to prevent brain damage in cerebral malaria ? Trends Parasitol. 2009 ; 25: 30-36.
390. Mihaila RG, Rezi EC, Boitan M., Zaharie AV, Olteanu A., Deac M. Erythropoietin and the pro-inflammatory cytokines in chronic C hepatitis. Hepatogastroenterology. 2009 ; 56: 751-755.
391. Picot S., Bienvenu AL, Konate S., et al. Safety of epoietin beta-quinine drug combination in children with cerebral malaria in Mali. Malar J. 2009 ; 8: 169.
392. MacRedmond R., Singhera GK, Dorscheid DR Erythropoietin inhibits respiratory epithelial cell apoptosis in a model of acute lung injury. Eur Respir J. 2009 ; 33: 1403-1414.
393. Tascilar O., Cakmak GK, Tekin IO, et al. Protective effects of erythropoietin against acute lung injury in a rat model of acute necrotizing pancreatitis. World J Gastroenterol. 2007 ; 13: 6172-6182.
394. Wu H., Dong G., Liu H., Xu B., Li D., Jing H. Erythropoietin attenuates ischemia-reperfusion induced lung injury by inhibiting tumor necrosis factor-alpha and matrix metalloproteinase-9 expression. Eur J Pharmacol. 2009 ; 602: 406-412.
395. Chang YK, Choi DE, Na KR, et al. Erythropoietin attenuates renal injury in an experimental model of rat unilateral ureteral obstruction via anti-inflammatory and anti-apoptotic effects. J Urol. 2009 ; 181: 1434-1443.
396. Chen HH, Tarng DC, Lee KF, Wu CY, Chen YC Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease. J Nephrol. 2008 ; 21: 543-549.
397. Song YR, Lee T., You SJ, et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol. 2009 ; 30: 253-260.
398. Luo YH, Li ZD, Liu LX, Dong GH Pretreatment with erythropoietin reduces hepatic ischemia-reperfusion injury. Hepatobiliary Pancreat Dis Int. 2009 ; 8: 294-299.
399. Schmeding M., Hunold G., Ariyakhagorn V., et al. Erythropoietin reduces ischemia-reperfusion injury after liver transplantation in rats [published online ahead of print March 20, 2009 ]. Transpl Int. 2009 ; 22: 738-746.
400. Ucan BH, Irkorucu O., Cakmak GK, et al. Erythropoietin: a possible cytoprotective cytokine in acute necrotizing pancreatitis. J Hepatobiliary Pancreat Surg. 2009 ; 16: 530-537.
401. Tsai JC, Song BJ, Wu L., Forbes M. Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma. 2007 ; 16: 567-571.
402. Wang ZY, Shen LJ, Tu L., et al. Erythropoietin protects retinal pigment epithelial cells from oxidative damage. Free Radic Biol Med. 2009 ; 46: 1032-1041.
403. Zhong YS, Liu XH, Cheng Y., Min YJ Erythropoietin with retrobulbar administration protects retinal ganglion cells from acute elevated intraocular pressure in rats. J Ocul Pharmacol Ther. 2008 ; 24: 453-459.
404. Toba H., Sawai N., Morishita M., et al. Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol. 2009 ; 612: 106-114.
405. Lagreze WA, Feltgen N., Bach M., Jehle T. Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol. 2009 ; 93: 1667-1671.
406. Di Giacomo V., Sancilio S., Caravatta L., Rana RA, Di Pietro R., Cataldi A. Regulation of CREB activation by P38 mitogen activated protein kinase during human primary erythroblast differentiation. Int J Immunopathol Pharmacol. 2009 ; 22: 679-688.
407. Koh SH, Noh MY, Cho GW, Kim KS, Kim SH Erythropoietin increases the motility of human bone marrow-multipotent stromal cells (hBM-MSCs) and enhances the production of neurotrophic factors from hBM-MSCs. Stem Cells Dev. 2009 ; 18: 411-421.
408. Tilling L., Chowienczyk P., Clapp B. Progenitors in motion: mechanisms of mobilization of endothelial progenitor cells. Br J Clin Pharmacol. 2009 ; 68: 484-492.
409. Mikati MA, Hokayem JA, Sabban ME Effects of a single dose of erythropoietin on subsequent seizure susceptibility in rats exposed to acute hypoxia at p10. Epilepsia. 2007 ; 48: 175-181.
410. Moon C., Krawczyk M., Paik D., et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther. 2006 ; 316: 999-1005.
411. Um M., Gross AW, Lodish HF A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal. 2007 ; 19: 634-645.
412. Arcasoy MO The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008 ; 141: 14-31.
413. Schumann C., Triantafilou K., Krueger S., et al. Detection of erythropoietin in exhaled breath condensate of nonhypoxic subjects using a multiplex bead array. Mediators Inflamm. 2006 ; 2006: 18061.
414. Li F., Chong ZZ, Maiese K. Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals. 2004 ; 13: 265-289.
415. Mojiminiyi OA, Abdella NA, Zaki MY, El Gebely SA, Mohamedi HM, Aldhahi WA Prevalence and associations of low plasma erythropoietin in patients with Type 2 diabetes mellitus. Diabet Med. 2006 ; 23: 839-844.
416. Symeonidis A., Kouraklis-Symeonidis A., Psiroyiannis A., et al. Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. Ann Hematol. 2006 ; 85: 79-85.
417. Thomas MC, Cooper ME, Tsalamandris C., MacIsaac R., Jerums G. Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med. 2005 ; 165: 466-469.
418. Teramo K., Kari MA, Eronen M., Markkanen H., Hiilesmaa V. High amniotic fluid erythropoietin levels are associated with an increased frequency of fetal and neonatal morbidity in type 1 diabetic pregnancies. Diabetologia. 2004 ; 47: 1695-1703.
419. Teramo KA, Widness JA Increased fetal plasma and amniotic fluid erythropoietin concentrations: markers of intrauterine hypoxia. Neonatology. 2009 ; 95: 105-116.
420. Kaindl AM, Sifringer M., Koppelstaetter A., et al. Erythropoietin protects the developing brain from hyperoxia-induced cell death and proteome changes. Ann Neurol. 2008 ; 64: 523-534.
421. Yis U., Kurul SH, Kumral A., et al. Effect of erythropoietin on oxygen-induced brain injury in the newborn rat. Neurosci Lett. 2008 ; 448: 245-249.
422. He Z., Huang L., Wu Y., Wang J., Wang H., Guo L. DDPH: improving cognitive deficits beyond its alpha 1-adrenoceptor antagonism in chronic cerebral hypoperfused rats. Eur J Pharmacol. 2008 ; 588: 178-188.
423. Berkingali N., Warnecke A., Gomes P., et al. Neurite outgrowth on cultured spiral ganglion neurons induced by erythropoietin. Hear Res. 2008 ; 243: 121-126.
424. Shah RC, Wilson RS, Tang Y., Dong X., Murray A., Bennett DA Relation of hemoglobin to level of cognitive function in older persons. Neuroepidemiology. 2009 ; 32: 40-46.
425. Bierer R., Peceny MC, Hartenberger CH, Ohls RK Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics. 2006 ; 118: e635 - e640.
426. Pillai A., Dhandapani KM, Pillai BA, Terry AV Jr, Mahadik SP Erythropoietin prevents haloperidol treatment-induced neuronal apoptosis through regulation of BDNF. Neuropsychopharmacology. 2008 ; 33: 1942-1951.
427. Silverberg DS, Wexler D., Iaina A., Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol. 2006 ; 26: 296-306.
428. Mason-Garcia M., Beckman BS, Brookins JW, et al. Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin. Kidney Int. 1990 ; 38: 969-975.
429. Namiuchi S., Kagaya Y., Ohta J., et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005 ; 45: 1406-1412.
430. Cariou A., Claessens YE, Pene F., et al. Early high-dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: a matched control study. Resuscitation. 2008 ; 76: 397-404.
431. Bakker WJ, van Dijk TB, Parren-van Amelsvoort M., et al. Differential regulation of Foxo3a target genes in erythropoiesis. Mol Cell Biol. 2007 ; 27: 3839-3854.
432. Avasarala JR, Konduru SS Recombinant erythropoietin down-regulates IL-6 and CXCR4 genes in TNF-alpha-treated primary cultures of human microvascular endothelial cells: implications for multiple sclerosis. J Mol Neurosci. 2005 ; 25: 183-189.
433. Leuner K., Hauptmann S., Abdel-Kader R., et al. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxid Redox Signal. 2007 ; 9: 1659-1675.
434. Miki T., Miura T., Yano T., et al. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J Pharmacol Exp Ther. 2006 ; 317: 68-75.
435. Barandon L., Couffinhal T., Ezan J., et al. Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation. 2003 ; 108: 2282-2289.
436. Emami KH, Corey E. When prostate cancer meets bone: control by wnts. Cancer Lett. 2007 ; 253: 170-179.
437. Hoogeboom D., Essers MA, Polderman PE, Voets E., Smits LM, Burgering BM Interaction of FOXO with {beta}-catenin inhibits {beta}-catenin/T cell factor activity. J Biol Chem. 2008 ; 283: 9224-9230.
438. Sun J., Jin T. Both Wnt and mTOR signaling pathways are involved in insulin-stimulated proto-oncogene expression in intestinal cells. Cell Signal. 2008 ; 20: 219-229.
439. Lynch RL, Konicek BW, McNulty AM, et al. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol Cancer Res. 2005 ; 3: 163-169.
440. Hegde PS, Rusnak D., Bertiaux M., et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther. 2007 ; 6: 1629-1640.
441. Hoekstra AV, Ward EC, Hardt JL, et al. Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gynecol Oncol. 2008 ; 108: 609-618.
442. Bakker WJ, Harris IS, Mak TW FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol Cell. 2007 ; 28: 941-953.
443. Dharmarajan TS, Widjaja D. Erythropoiesis-stimulating agents in anemia: use and misuse. J Am Med Dir Assoc. 2009 ; 10: 607-616.
444. Ioka T., Tsuruoka S., Ito C., et al. Hypertension induced by erythropoietin has a correlation with truncated erythropoietin receptor mRNA in endothelial progenitor cells of hemodialysis patients. Clin Pharmacol Ther. 2009 ; 86: 154-159.
445. Sigounas G., Salleng KJ, Mehlhop PD, Sigounas DG Erythropoietin ameliorates chemotherapy-induced fibrosis of the lungs in a preclinical murine model. Int J Cancer. 2008 ; 122: 2851-2857.
446. Kokhaei P., Abdalla AO, Hansson L., et al. Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res. 2007 ; 13: 3536-3544.
447. Maiese K., Li F., Chong ZZ Erythropoietin and cancer. JAMA. 2005 ; 293: 1858-1859.
448. Hardee ME, Rabbani ZN, Arcasoy MO, et al. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther. 2006 ; 5: 356-361.
449. Lai SY, Grandis JR Understanding the presence and function of erythropoietin receptors on cancer cells. J Clin Oncol. 2006 ; 24: 4675-4676.
450. Ceelen W., Boterberg T., Smeets P., et al. Recombinant human erythropoietin alpha modulates the effects of radiotherapy on colorectal cancer microvessels. Br J Cancer. 2007 ; 96: 692-700.